Risk of port-site metastases in pelvic cancers after robotic surgery

• Published in: European journal of surgical oncology Vol. 41; no. 4; pp. 599 - 603
• Main Authors: Seror, J, Bats, A.-S, Bensaïd, C, Douay-Hauser, N, Ngo, C, Lécuru, F
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2015
• Subjects: Abdominal Wall; Adult; Aged; Aged, 80 and over; Aorta; Endometrial Neoplasms - pathology; Endometrial Neoplasms - surgery; Female; Hematology, Oncology and Palliative Medicine; Humans; Hysterectomy - adverse effects; Lymph Node Excision - adverse effects; Middle Aged; Neoplasm Seeding; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Ovariectomy - adverse effects; Pelvic cancer; Pelvis; Port-site metastasis; Retrospective Studies; Robotic surgery; Robotic Surgical Procedures - adverse effects; Salpingectomy - adverse effects; Surgery; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - surgery; Robotic surgery; Port-site metastasis; Pelvic cancer
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2015.01.003

Abstract Objective To assess the risk of occurrence of port-site metastases after robotic surgery for pelvic cancer. Methods Retrospective study from June 2007 to March 2013 of patients with gynecologic cancer who underwent robot-assisted surgery. We collected preoperative data, including characteristics of patients and FIGO stage, intraoperative data (surgery performed, number of ports), and postoperative data (occurrence of metastases, occurrence of port-site metastases). Results 115 patients were included in the study: 61 with endometrial cancer, 50 with cervical cancer and 4 with ovarian cancer. The surgical procedures performed were: hysterectomy with bilateral salpingo-oophorectomy, radical hysterectomy, pelvic lymphadenectomy, para-aortic lymphadenectomy and omentectomy. All surgical procedures required the introduction of 4 ports, 3 for the robot and 1 for the assistant. With a mean follow-up of 504.4 days (507.7 days for endometrial cancer, 479.5 days for cervical cancer, and 511.3 for ovarian cancer), we observed 9 recurrences but no port-site metastasis. Conclusion No port-site metastasis has occurred in our series. However, larger, prospective and randomized works are needed to formally conclude.